Review Reports
- Barbara Verro 1,*,
- Roberta Oliveri 2 and
- Carmelo Saraniti 1,†
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsDear Authors, the manuscript tackles a pertinent and timely subject within the discipline and offers a well-organized overview of the mechanisms and clinical aspects examined. Nevertheless, several elements could be enhanced to bolster the scientific rigor and clinical significance of the manuscript:
- Although the manuscript outlines essential pathways and mechanisms, the discussion tends to be more descriptive than integrative. The authors are urged to present a more critical synthesis of the interactions among various pathways within the tumor microenvironment and to elucidate the translational significance of these mechanisms, especially concerning therapeutic targeting.
- The manuscript addresses the role of the tumor microenvironment; however, this section could be further elaborated and structured more clearly. Specifically, the interactions among immune cells, stromal components, and tumor cells could be more explicitly integrated, and the discussion could better link molecular findings with emerging therapeutic strategies (e.g., immunomodulation, targeted therapies) in HNSCC, including immune modulation, stromal interactions, and signaling pathway integration (please refer to: https://pmc.ncbi.nlm.nih.gov/articles/PMC12573164/) to enhance the conceptual framework and provide a more translationally focused discussion.
- The manuscript would gain from a more pronounced emphasis on clinical applicability. In particular, how the mechanisms described may affect treatment decisions, potential biomarkers for prognosis or therapy selection, and the challenges in translating preclinical findings into clinical practice.
- The current iteration of the manuscript tends to summarize findings without considering inconsistencies across studies, the limitations of existing evidence, and the gaps in current knowledge. A more critical perspective would augment the scientific value of the manuscript.
Best regards!
Comments on the Quality of English LanguageThe manuscript is generally comprehensible; however, minor to moderate language editing is advisable to enhance clarity, precision, and flow.
Author Response
Comment 1: Although the manuscript outlines essential pathways and mechanisms, the discussion tends to be more descriptive than integrative. The authors are urged to present a more critical synthesis of the interactions among various pathways within the tumor microenvironment and to elucidate the translational significance of these mechanisms, especially concerning therapeutic targeting.
Response 1: We thank the Reviewer for this comment. We have added the Discussion section to provide a more integrative and critical synthesis of metabolic interactions within the tumor microenvironment in LSCC. Specifically, we have emphasized the interconnected nature of metabolic pathways, highlighting how glycolysis, amino acid metabolism, lipid metabolism, and iron handling converge on shared functional outputs such as redox homeostasis, immune modulation, and tumor adaptation. To strengthen the mechanistic integration, we have incorporated concrete examples of metabolic crosstalk, including lactate-mediated immunosuppression, mitochondrial glutamine metabolism and its regulation by CECR2, as well as the interplay between lipid metabolism and ferroptosis. In addition, we have expanded the translational perspective by explicitly discussing how these interconnected pathways create therapeutic vulnerabilities and by outlining the rationale for combinatorial strategies targeting multiple metabolic nodes, including their potential integration with immunotherapy and ferroptosis-based approaches. These revisions are intended to move beyond a descriptive overview and provide a more clinically relevant interpretation of metabolic reprogramming in LSCC (lines 587-684).
Comment 2: The manuscript addresses the role of the tumor microenvironment; however, this section could be further elaborated and structured more clearly. Specifically, the interactions among immune cells, stromal components, and tumor cells could be more explicitly integrated, and the discussion could better link molecular findings with emerging therapeutic strategies (e.g., immunomodulation, targeted therapies) in HNSCC, including immune modulation, stromal interactions, and signaling pathway integration (please refer to: https://pmc.ncbi.nlm.nih.gov/articles/PMC12573164/) to enhance the conceptual framework and provide a more translationally focused discussion.
Response 2: We thank the Reviewer for this suggestion. In response, we have revised and expanded the Discussion section addressing the tumor microenvironment (TME) to improve its structure and conceptual clarity. Specifically, we have introduced a more integrated framework describing the dynamic interactions among tumor cells, immune populations, and stromal components in LSCC. The revised text highlights the bidirectional crosstalk between these cellular compartments, emphasizing how immune and stromal elements cooperate with tumor cells to shape immunosuppression, metabolic adaptation, and therapeutic resistance. In addition, we have strengthened the link between molecular mechanisms - particularly metabolic reprogramming - and their functional impact on the TME. Finally, we have expanded the translational perspective by discussing emerging therapeutic strategies in HNSCC, including immunomodulatory approaches, targeting of stromal interactions, and combined metabolic and immune-based therapies. These modifications were made in line with the suggested reference (ref 52).
Comment 3: The manuscript would gain from a more pronounced emphasis on clinical applicability. In particular, how the mechanisms described may affect treatment decisions, potential biomarkers for prognosis or therapy selection, and the challenges in translating preclinical findings into clinical practice. We thank the Reviewer for this comment. In response, we have expanded the Discussion to more explicitly address the clinical applicability of the metabolic mechanisms described in LSCC. Specifically, we have highlighted how metabolic reprogramming may influence therapeutic decision-making, emphasizing the potential role of metabolic phenotypes in guiding patient stratification and personalized treatment approaches. We have also strengthened the discussion of potential biomarkers, including metabolic signatures and key regulatory molecules, in relation to prognosis and prediction of therapeutic response. In addition, we have incorporated a dedicated discussion on the challenges of translating preclinical findings into clinical practice, addressing issues such as metabolic plasticity, tumor heterogeneity, and the current lack of robust clinical validation. These additions aim to provide a more clinically oriented perspective and to bridge the gap between mechanistic insights and their potential application in patient management.
Comment 4: The current iteration of the manuscript tends to summarize findings without considering inconsistencies across studies, the limitations of existing evidence, and the gaps in current knowledge. A more critical perspective would augment the scientific value of the manuscript.
Response 4: We thank the Reviewer for this comment. We have added in the Discussion a more critical perspective on the current state of evidence. Specifically, we have added a dedicated section highlighting key limitations and inconsistencies across studies, including the context-dependent nature of metabolic phenotypes, variability across experimental models, and the limited translatability of preclinical findings. We have also discussed existing gaps in knowledge, particularly regarding the identification and validation of robust metabolic biomarkers and the challenges posed by tumor heterogeneity and metabolic plasticity. These additions aim to provide a more balanced and critical interpretation of the available evidence and to better contextualize the potential clinical implications of metabolic reprogramming in LSCC.
The manuscript has been carefully revised for English language and style by a native English speaker with expertise in the field.
Reviewer 2 Report
Comments and Suggestions for AuthorsDear authors,
Kindly highlight the novelty of your work in the introduction and abstract sections.
Kindly add a challenges section in this area. How can your study fill the gaps?
Kindly highlight the biology of this cancer along with one figure.
how drug discovery and drug designing can be carried out in this area.
Author Response
Comment 1: Kindly highlight the novelty of your work in the introduction and abstract sections.
Response 1: We thank the Reviewer for this suggestion. We have revised both the Abstract and the Introduction to more clearly highlight the novelty of our work. Specifically, we have emphasized the integrative nature of our review, which combines metabolic reprogramming with tumor microenvironment interactions and immune modulation in LSCC, as well as its translational focus on potential biomarkers and therapeutic strategies. These additions aim to better clarify the originality and clinical relevance of our manuscript.
Comment 2: Kindly add a challenges section in this area. How can your study fill the gaps?
Response 2: We thank the Reviewer for this suggestion. We have added a “Challenges and future directions” section addressing the current challenges and future directions in the study of metabolic reprogramming in LSCC. Specifically, we have highlighted key limitations in the field, including metabolic plasticity, tumor heterogeneity, and the complexity of tumor microenvironment interactions, as well as the lack of validated clinical biomarkers. In addition, we have clarified how our review contributes to addressing these gaps by providing an integrated framework that links metabolic pathways with immune and stromal components, and by emphasizing the translational relevance of these interactions for biomarker development and therapeutic strategies (lines 711-733).
Comment 3: Kindly highlight the biology of this cancer along with one figure.
Response 3: We have added a schematic figure summarizing the biological features of LSCC, integrating metabolic reprogramming, tumor microenvironment interactions, and potential therapeutic targets. (Fig 5)
Comment 4: How drug discovery and drug designing can be carried out in this area.
Response 4: We thank the Reviewer for this suggestion. We have expanded the Discussion to include a dedicated perspective on drug discovery and therapeutic design in LSCC. Specifically, we have outlined how the metabolic pathways described in this review may serve as potential druggable targets, and how biomarker-driven approaches could support patient stratification and personalized therapy. We have also emphasized the importance of rational combinatorial strategies integrating metabolic inhibitors with immunotherapy and other treatment modalities, as well as the role of metabolic profiling in guiding drug development. These additions aim to strengthen the translational relevance of the manuscript and to provide a clearer link between mechanistic insights and therapeutic innovation.
Reviewer 3 Report
Comments and Suggestions for AuthorsThe manuscript demonstrates a strong conceptual framework; however, several aspects require clarification, expansion, and structural refinement before it can be considered for publication.
- The authors should more clearly articulate what differentiates this review from existing literature on metabolic reprogramming in head and neck cancers, for example, by adding a brief section titled “Unique metabolic features of LSCC versus other HNSCC subtypes.” This section should clarify whether laryngeal squamous cell carcinoma exhibits distinct metabolic signatures compared with other subtypes, such as oral or oropharyngeal cancers.
- It will be more beneficial if authors should be included a dedicated section titled “Therapeutic Implications of Metabolic Reprogramming in LSCC,” which should discuss current or emerging metabolism‑targeting drugs, summarise relevant clinical trials where available, and highlight potential biomarkers such as metabolic imaging approaches and circulating metabolites.
Author Response
Comment 1: The authors should more clearly articulate what differentiates this review from existing literature on metabolic reprogramming in head and neck cancers, for example, by adding a brief section titled “Unique metabolic features of LSCC versus other HNSCC subtypes.” This section should clarify whether laryngeal squamous cell carcinoma exhibits distinct metabolic signatures compared with other subtypes, such as oral or oropharyngeal cancers.
Response 1: We thank the Reviewer for this suggestion. We have added a section entitled “Unique metabolic features of LSCC compared with other HNSCC subtypes” before the Discussion. In this section, we highlight key biological and metabolic differences between LSCC and other HNSCC entities, including variations in etiological factors, tumor microenvironment composition, and metabolic adaptations (lines 566-586).
Comment 2: It will be more beneficial if authors should be included a dedicated section titled “Therapeutic Implications of Metabolic Reprogramming in LSCC,” which should discuss current or emerging metabolism‑targeting drugs, summarise relevant clinical trials where available, and highlight potential biomarkers such as metabolic imaging approaches and circulating metabolites.
Response 2: We thank the Reviewer for this suggestion. We have added a dedicated section entitled “Therapeutic Implications of Metabolic Reprogramming in LSCC.” In this section, we discuss emerging metabolism-targeting strategies, clarify the current level of clinical evidence, summarize relevant clinical-trial experience where available, and expand the biomarker perspective by including metabolic imaging approaches and circulating biomarkers. We also explicitly note that most current evidence comes from broader HNSCC settings or early-phase studies, highlighting the need for LSCC-specific clinical validation (lines 685-710).
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsDear Authors, you have significantly increased the quality of the manuscript by incorporating my suggestions. I have no further comments. Congrats!
Reviewer 3 Report
Comments and Suggestions for AuthorsNo comments